AbCellera Biologics Inc.
ABCL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $862 | $1,651 | $2,888 | $3,943 |
| - Cash | $156 | $133 | $387 | $476 |
| + Debt | $65 | $77 | $82 | $40 |
| Enterprise Value | $771 | $1,595 | $2,583 | $3,507 |
| Revenue | $29 | $38 | $485 | $375 |
| % Growth | -24.2% | -92.2% | 29.4% | – |
| Gross Profit | $29 | $38 | $419 | $330 |
| % Margin | 100% | 100% | 86.3% | 87.9% |
| EBITDA | -$204 | -$192 | $260 | $239 |
| % Margin | -708% | -505.3% | 53.6% | 63.7% |
| Net Income | -$163 | -$146 | $159 | $153 |
| % Margin | -564.8% | -385% | 32.7% | 40.9% |
| EPS Diluted | -0.55 | -0.51 | 0.5 | 0.48 |
| % Growth | -7.8% | -202% | 4.2% | – |
| Operating Cash Flow | -$109 | -$44 | $277 | $245 |
| Capital Expenditures | -$78 | -$78 | -$73 | -$58 |
| Free Cash Flow | -$187 | -$121 | $205 | $186 |